Simultaneous Determination of Lamotrigine, Topiramate, Oxcarbazepine, and 10,11-dihydro-10-hydroxycarbazepine in Human Blood Plasma by UHPLC-MS/MS

Author(s): Qing Zhao, Siyao Jin, Qingyang Liu, Zhigang Zhao, Weixing Feng, Shenghui Mei*

Journal Name: Current Analytical Chemistry

Volume 16 , Issue 8 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Lamotrigine (LTG), topiramate (TPM), and oxcarbazepine (OXC) are commonly used antiepileptic drugs. The bioactivity and toxicity of these drugs were related to their blood concentrations which varied greatly among individuals and required to be monitored for dose adjustment. However, the commercial method for monitoring of these drugs is not available in China.

Methods: A UHPLC-MS/MS method for simultaneous determination of LTG, TPM, OXC, and OXC active metabolite (10,11-dihydro-10-hydroxycarbazepine, MHD) was developed and validated according to the guidelines and applied in clinical practice.

Results: The separation was achieved by using methanol and water (both contain 0.1% formic acid) at 0.4 mL/min under gradient elution within 3 min. For all analytes, the isotope internal standard was used; the selectivity was good without significant carry over; LTG and TPM were linear between 0.06 to 12 mg/L while OXC and MHD were linear between 0.03 to 6 mg/L, the upper limit could be 10-fold higher because 10-fold dilution with water did not affect the results; the intra-day and interday bias and imprecision were -13.11% to 5.42% and < 13.32%; the internal standard normalized recovery and matrix factor were 90.95% to 111.94% and 95.57% to 109.91%; and all analytes were stable under tested conditions. LTG and OXC-D4 shared two ion pairs m/z 257.1 > 212.0 and 257.1 > 184.0, and m/z 257.1 > 240.0 was suggested for OXC-D4 quantitation. Lamotrigine and lamotrigine- 13C3 shared three ion pairs m/z 259.0 > 214.0, 259.0 > 168.0 and 259.0 > 159.0, and m/z 259.0 > 144.9 was suggested for LTG-13C3 quantitation. CBZ had a slight influence on OXC analysis only at 0.225 mg/L (bias, 20.24%) but did not affect MHD analysis. Optimization of chromatography conditions was useful to avoid the influence of isobaric mass transitions on analysis. This method has been successfully applied in 208 patients with epilepsy for dose adjustment.

Conclusion: An accurate, robust, rapid, and simple method for simultaneous determination of LTG, TPM, OXC, and MHD by UHPLC-MS/MS was developed, validated, and successfully applied in patients with epilepsy for dose adjustment. The experiences during method development, validation, and application might be helpful for other researchers.

Keywords: Human plasma, lamotrigine, method development and validation, oxcarbazepine, topiramate, UHPLC-MS/MS.

[1]
Glauser, T.; Ben-Menachem, E.; Bourgeois, B.; Cnaan, A.; Guerreiro, C.; Kälviäinen, R.; Mattson, R.; French, J.A.; Perucca, E.; Tomson, T.; Guidelines, I.S.A. ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2013, 54(3), 551-563.
[http://dx.doi.org/10.1111/epi.12074] [PMID: 23350722]
[2]
Werz, M.A. Pharmacotherapeutics of epilepsy: Use of lamotrigine and expectations for lamotrigine extended release. Ther. Clin. Risk Manag., 2008, 4(5), 1035-1046.
[http://dx.doi.org/10.2147/TCRM.S3343] [PMID: 19209284]
[3]
Patsalos, P.N.; Berry, D.J.; Bourgeois, B.F.; Cloyd, J.C.; Glauser, T.A.; Johannessen, S.I.; Leppik, I.E.; Tomson, T.; Perucca, E. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49(7), 1239-1276.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01561.x] [PMID: 18397299]
[4]
Lin, W.W.; Li, X.W.; Jiao, Z.; Zhang, J.; Rao, X.; Zeng, D.Y.; Lin, X.H.; Wang, C.L. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens. Eur. J. Clin. Pharmacol., 2018, 75, 318-392.
[http://dx.doi.org/10.1007/s00228-018-2600-8] [PMID: 30456415]
[5]
Xu, S.; Liu, L.; Chen, Y.; Liu, M.; Lu, T.; Wang, H.; Liu, S.; Zhao, M.; Zhao, L. Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. Eur. J. Clin. Pharmacol., 2018, 74(5), 583-591.
[http://dx.doi.org/10.1007/s00228-018-2414-8] [PMID: 29340733]
[6]
Bae, E.K.; Lee, J.; Shin, J.W.; Moon, J.; Lee, K.J.; Shin, Y.W.; Kim, T.J.; Shin, D.; Jang, I.J.; Lee, S.K. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis. Seizure, 2016, 37, 8-12.
[http://dx.doi.org/10.1016/j.seizure.2016.02.002] [PMID: 26908152]
[7]
Wegner, I.; Wilhelm, A.J.; Sander, J.W.; Lindhout, D. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav., 2013, 29(1), 217-221.
[http://dx.doi.org/10.1016/j.yebeh.2013.07.016] [PMID: 23995050]
[8]
Lin, W.W.; Wang, C.L.; Jiao, Z.; Yu, X.L.; Zhang, J.; Zhang, W.B.; Lin, R.F.; Lin, S.; Lin, X.H. Glomerular filtration rate is a major predictor of clearance of oxcarbazepine active metabolite in adult Chinese epileptic patients: A population pharmacokinetic analysis. Ther. Drug Monit., 2019, 41(5), 665-673.
[http://dx.doi.org/10.1097/FTD.0000000000000644] [PMID: 31033858]
[9]
Takeuchi, M.; Yano, I.; Ito, S.; Sugimoto, M.; Yamamoto, S.; Yonezawa, A.; Ikeda, A.; Matsubara, K. Population pharmacokinetics of topiramate in japanese pediatric and adult patients with epilepsy using routinely monitored data. Ther. Drug Monit., 2017, 39(2), 124-131.
[http://dx.doi.org/10.1097/FTD.0000000000000383] [PMID: 28230619]
[10]
Wang, Z.Z.; Zhang, Y.F.; Huang, W.C.; Wang, X.P.; Ni, X.J.; Lu, H.Y.; Hu, J.Q.; Deng, S.H.; Zhu, X.Q.; Xie, H.S.; Chen, H.Z.; Zhang, M.; Qiu, C.; Wen, Y.G.; Shang, D.W. Effects of comedication and genetic factors on the population pharmacokinetics of lamotrigine: A prospective analysis in chinese patients with epilepsy. Front. Pharmacol., 2019, 10, 832.
[http://dx.doi.org/10.3389/fphar.2019.00832] [PMID: 31404235]
[11]
Besag, F.M.; Berry, D.J.; Pool, F.; Newbery, J.E.; Subel, B. Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? Epilepsia, 1998, 39(2), 183-187.
[http://dx.doi.org/10.1111/j.1528-1157.1998.tb01356.x] [PMID: 9577998]
[12]
Alabi, A.; Todd, A.; Husband, A.; Reilly, J. Safety profile of lamotrigine in overdose. Ther. Adv. Psychopharmacol., 2016, 6(6), 369-381.
[http://dx.doi.org/10.1177/2045125316656707] [PMID: 28008350]
[13]
Pennell, P.B.; Peng, L.; Newport, D.J.; Ritchie, J.C.; Koganti, A.; Holley, D.K.; Newman, M.; Stowe, Z.N. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 2008, 70(22 Pt 2), 2130-2136.
[http://dx.doi.org/10.1212/01.wnl.0000289511.20864.2a] [PMID: 18046009]
[14]
Italiano, D.; Perucca, E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: An update. Clin. Pharmacokinet., 2013, 52(8), 627-645.
[http://dx.doi.org/10.1007/s40262-013-0067-4] [PMID: 23640503]
[15]
Hussein, Z.; Posner, J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. J. Clin. Pharmacol., 1997, 43(5), 457-465.
[http://dx.doi.org/10.1046/j.1365-2125.1997.00594.x] [PMID: 9159559]
[16]
Twyman, R.E.; Ben-Menachem, E.; Veloso, F.; Bomhof, M.A.M.; Wu, S.C.; Pledger, G. Plasma topiramate (TPM) concentration vs. therapeutic response during monotherapy. Epilepsia, 1999, 40, 111-112.
[17]
Christensen, J.; Andreasen, F.; Poulsen, J.H.; Dam, M. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology, 2003, 61(9), 1210-1218.
[http://dx.doi.org/10.1212/01.WNL.0000091867.09720.6B] [PMID: 14610122]
[18]
Britzi, M.; Perucca, E.; Soback, S.; Levy, R.H.; Fattore, C.; Crema, F.; Gatti, G.; Doose, D.R.; Maryanoff, B.E.; Bialer, M. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia, 2005, 46(3), 378-384.
[http://dx.doi.org/10.1111/j.0013-9580.2005.55204.x] [PMID: 15730535]
[19]
Rosenfeld, W.E.; Liao, S.; Kramer, L.D.; Anderson, G.; Palmer, M.; Levy, R.H.; Nayak, R.K. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia, 1997, 38(3), 324-333.
[http://dx.doi.org/10.1111/j.1528-1157.1997.tb01124.x] [PMID: 9070595]
[20]
de Sousa Maia, M.B.; do Nascimento, D.F.; Martins, I.L.; Cunha, A.N.; de Lima, F.E.; Bezerra, F.A.; de Moraes, M.O.; de Moraes, M.E. Simultaneous quantitative analysis of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine in human plasma by liquid chromatography-electrospray tandem mass spectrometry. J. Pharm. Biomed. Anal., 2007, 45(2), 304-311.
[http://dx.doi.org/10.1016/j.jpba.2007.08.001] [PMID: 17869472]
[21]
Borusiak, P.; Korn-Merker, E.; Holert, N.; Boenigk, H.E. Oxcarbazepine in treatment of childhood epilepsy: A survey of 46 children and adolescents. J. Epilepsy, 1998, 11(6), 355-360.
[http://dx.doi.org/10.1016/S0896-6974(98)00041-3]
[22]
Battino, D.; Estienne, M.; Avanzini, G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin. Pharmacokinet., 1995, 29(5), 341-369.
[http://dx.doi.org/10.2165/00003088-199529050-00004] [PMID: 8582119]
[23]
Christensen, J.; Sabers, A.; Sidenius, P. Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy. Neurology, 2006, 67(8), 1497-1499.
[http://dx.doi.org/10.1212/01.wnl.0000240047.11166.0e] [PMID: 17060586]
[24]
Rouan, M.C.; Lecaillon, J.B.; Godbillon, J.; Menard, F.; Darragon, T.; Meyer, P.; Kourilsky, O.; Hillion, D.; Aldigier, J.C.; Jungers, P. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur. J. Clin. Pharmacol., 1994, 47(2), 161-167.
[http://dx.doi.org/10.1007/BF00194967] [PMID: 7859804]
[25]
Bahrami, G.; Mirzaeei, S.; Mohammadi, B.; Kiani, A. High performance liquid chromatographic determination of topiramate in human serum using UV detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2005, 822(1-2), 322-325.
[http://dx.doi.org/10.1016/j.jchromb.2005.05.032] [PMID: 15996538]
[26]
Serralheiro, A.; Alves, G.; Fortuna, A.; Rocha, M.; Falcão, A. First HPLC-UV method for rapid and simultaneous quantification of phenobarbital, primidone, phenytoin, carbamazepine, carbamazepine-10,11-epoxide, 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine, lamotrigine, oxcarbazepine and licarbazepine in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2013, 925, 1-9.
[http://dx.doi.org/10.1016/j.jchromb.2013.02.026] [PMID: 23507454]
[27]
Baldelli, S.; Cattaneo, D.; Giodini, L.; Baietto, L.; Di Perri, G.; D’Avolio, A.; Clementi, E. Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clin. Chem. Lab. Med., 2015, 53(3), 435-444.
[http://dx.doi.org/10.1515/cclm-2014-0472] [PMID: 25153419]
[28]
Antonilli, L.; Brusadin, V.; Filipponi, F.; Guglielmi, R.; Nencini, P. Development and validation of an analytical method based on high performance thin layer chromatography for the simultaneous determination of lamotrigine, zonisamide and levetiracetam in human plasma. J. Pharm. Biomed. Anal., 2011, 56(4), 763-770.
[http://dx.doi.org/10.1016/j.jpba.2011.07.018] [PMID: 21840147]
[29]
Antunes, N.J.; Wichert-Ana, L.; Coelho, E.B.; Della Pasqua, O.; Alexandre, Junior, V.; Takayanagui, O.M.; Marques, M.P.; Lanchote, V.L. Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers. J. Pharm. Biomed. Anal., 2018, 149, 442-447.
[http://dx.doi.org/10.1016/j.jpba.2017.11.041] [PMID: 29169112]
[30]
Milosheska, D.; Roškar, R. A novel LC-MS/MS method for the simultaneous quantification of topiramate and its main metabolites in human plasma. J. Pharm. Biomed. Anal., 2017, 138, 180-188.
[http://dx.doi.org/10.1016/j.jpba.2017.02.003] [PMID: 28214451]
[31]
Tai, S.S.; Yeh, C.Y.; Phinney, K.W. Development and validation of a reference measurement procedure for certification of phenytoin, phenobarbital, lamotrigine, and topiramate in human serum using isotope-dilution liquid chromatography/tandem mass spectrometry. Anal. Bioanal. Chem., 2011, 401(6), 1915-1922.
[http://dx.doi.org/10.1007/s00216-011-5251-5] [PMID: 21874530]
[32]
Karinen, R.; Vindenes, V.; Hasvold, I.; Olsen, K.M.; Christophersen, A.S.; Øiestad, E. Determination of a selection of anti-epileptic drugs and two active metabolites in whole blood by reversed phase UPLC-MS/MS and some examples of application of the method in forensic toxicology cases. Drug Test. Anal., 2015, 7(7), 634-644.
[http://dx.doi.org/10.1002/dta.1733] [PMID: 25331692]
[33]
Kim, K.B.; Seo, K.A.; Kim, S.E.; Bae, S.K.; Kim, D.H.; Shin, J.G. Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. J. Pharm. Biomed. Anal., 2011, 56(4), 771-777.
[http://dx.doi.org/10.1016/j.jpba.2011.07.019] [PMID: 21840666]
[34]
Hahn, R.Z.; Antunes, M.V.; Costa Arnhold, P.; Andriguetti, N.B.; Verza, S.G.; Linden, R. Determination of topiramate in dried blood spots using single-quadrupole gas chromatography-mass spectrometry after flash methylation with trimethylanilinium hydroxide. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2017, 1046, 131-137.
[http://dx.doi.org/10.1016/j.jchromb.2017.01.047] [PMID: 28178597]
[35]
Ghatol, S.; Vithlani, V.; Gurule, S.; Khuroo, A.; Monif, T.; Partani, P. Liquid chromatography tandem mass spectrometry method for the estimation of lamotrigine in human plasma: Application to a pharmacokinetic study. J. Pharm. Anal., 2013, 3(2), 75-83.
[http://dx.doi.org/10.1016/j.jpha.2012.09.001] [PMID: 29403800]
[36]
Dupouey, J.; Doudka, N.; Belo, S.; Blin, O.; Guilhaumou, R. Simultaneous determination of four antiepileptic drugs in human plasma samples using an ultra-high-performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. Biomed. Chromatogr., 2016, 30(12), 2053-2060.
[http://dx.doi.org/10.1002/bmc.3789] [PMID: 27417975]
[37]
Ni, Y.; Zhou, Y.; Xu, M.; He, X.; Li, H.; Haseeb, S.; Chen, H.; Li, W. Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. J. Pharm. Biomed. Anal., 2015, 107, 444-449.
[http://dx.doi.org/10.1016/j.jpba.2015.01.035] [PMID: 25668796]
[38]
Conway, J.M.; Birnbaum, A.K.; Marino, S.E.; Cloyd, J.C.; Remmel, R.P. A sensitive capillary GC-MS method for analysis of topiramate from plasma obtained from single-dose studies. Biomed. Chromatogr., 2012, 26(9), 1071-1076.
[http://dx.doi.org/10.1002/bmc.1749] [PMID: 22223467]
[39]
FDA. Guidance for industry: bioanalytical method validation., https://www.fda.gov/media/70858/download2018
[41]
Palte, M.J.; Basu, S.S.; Dahlin, J.L.; Gencheva, R.; Mason, D.; Jarolim, P.; Petrides, A.K. Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method for the concurrent measurement of gabapentin, lamotrigine, levetiracetam, monohydroxy derivative of oxcarbazepine, and zonisamide concentrations in serum in a clinical setting. Ther. Drug Monit., 2018, 40(4), 469-476.
[http://dx.doi.org/10.1097/FTD.0000000000000516] [PMID: 29994986]
[42]
Namdev, K.K.; Dwivedi, J.; Chilkoti, D.C.; Sharma, S. A simple, rapid and stability indicating validated method for quantification of lamotrigine in human plasma and dry plasma spot using LC-ESI-MS/MS: Application in clinical study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2018, 1072, 362-369.
[http://dx.doi.org/10.1016/j.jchromb.2017.11.040] [PMID: 29223050]
[43]
Mano, Y. LC-MS-MS Determination of oxcarbazepine and an active metabolite in human plasma for clinical application. J. Chromatogr. Sci., 2018, 56(8), 687-694.
[http://dx.doi.org/10.1093/chromsci/bmy040] [PMID: 29733349]
[44]
Matar, K.M. Therapeutic drug monitoring of topiramate by liquid chromatography-tandem mass spectrometry. Clin. Chim. Acta, 2010, 411(9-10), 729-734.
[http://dx.doi.org/10.1016/j.cca.2010.02.003] [PMID: 20138857]
[45]
Paglia, G.; D’Apolito, O.; Garofalo, D.; Scarano, C.; Corso, G. Development and validation of a LC/MS/MS method for simultaneous quantification of oxcarbazepine and its main metabolites in human serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 860(2), 153-159.
[http://dx.doi.org/10.1016/j.jchromb.2007.10.025] [PMID: 17996501]
[46]
Kudriakova, T.B.; Sirota, L.A.; Rozova, G.I.; Gorkov, V.A. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br. J. Clin. Pharmacol., 1992, 33(6), 611-615.
[http://dx.doi.org/10.1111/j.1365-2125.1992.tb04089.x] [PMID: 1389933]
[47]
Kaiser, E.; Prasse, C.; Wagner, M.; Bröder, K.; Ternes, T.A. Transformation of oxcarbazepine and human metabolites of carbamazepine and oxcarbazepine in wastewater treatment and sand filters. Environ. Sci. Technol., 2014, 48(17), 10208-10216.
[http://dx.doi.org/10.1021/es5024493] [PMID: 25137395]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 8
Year: 2020
Published on: 25 October, 2020
Page: [1010 - 1021]
Pages: 12
DOI: 10.2174/1573411016666200108143049
Price: $65

Article Metrics

PDF: 18
HTML: 4